Melanoma Unveiled: Decoding the Enigmatic Malignancy

TANMAY MEHTA[1], SAKSHI AOLE[2], DR. VIKAS JAIN[3]
[1, 2, 3] *Mahakal Institute of Pharmaceutical Studies, Ujjain*

Abstract*— Melanoma, a malignant tumor originating from melanocytes, is one of the most aggressive and lethal forms of skin cancer. Despite significant advances in our understanding of its molecular pathogenesis, melanoma remains a formidable clinical challenge. This comprehensive review provides an in-depth exploration of the current knowledge and emerging trends in melanoma research. We delve into the epidemiology and risk factors associated with melanoma, highlighting the importance of early detection and preventive measures. The review then elucidates the intricate molecular mechanisms underpinning melanoma development, encompassing genetic alterations, signaling pathways, and tumor microenvironment interactions. Diagnostic approaches, including established and novel techniques, are critically evaluated, emphasizing the importance of accurate and timely diagnosis for effective management. Furthermore, we examine the latest therapeutic strategies, ranging from conventional treatments to innovative targeted therapies and immunotherapies, providing a critical analysis of their efficacy, limitations, and potential future directions. Additionally, we highlight the unique challenges posed by advanced and metastatic melanoma, discussing the ongoing efforts to combat resistance mechanisms and improve patient outcomes. The review also explores the emerging field of precision medicine and its potential implications for personalized melanoma treatment. Finally, we discuss the current gaps in knowledge and outline future research avenues, underscoring the importance of interdisciplinary collaborations and translational research in advancing our understanding and management of this complex malignancy.

I. INTRODUCTION

Melanoma is a tumor produced by the malignant transformation of melanocytes. Melanocytes are dried from the neural Crest; consequently, Melanomas, although they usually occurs on the skin, can arise in other locations where neural crest cells migrate, such as gastrointestinal track and brain. Basically, it is a form of Cancer that begins in melanocytes (the cells that make the pigment Melanin and give the skin it's tan or brown colour) starts to grow out of control. It may begin in a mole (skin melanoma), but can also begin in other pigment tissues such as eye or in intestines. All over we can say that it is the most serious type of skin cancer, Melanoma occurs when the pigment producing cell that gives colour to the skin become cancerous.

A melanoma is a tumor produced by the malignant transformation of melanocytes. Melanocytes are derived from the neural crest; consequently, melanomas, although they usually occur on the skin, can arise in other locations where neural crest cells migrate, such as the gastrointestinal tract and brain. The five-year relative survival rate for patients with stage 0 melanoma is 97%, compared with about 10% for those with stage IV disease.

The incidence of malignant melanoma is rapidly increasing worldwide, and this increase is occurring at a faster rate than that of any other cancer except lung cancer in women. Melanoma is more common in Whites than in Blacks and Asians. Overall, melanoma is the fifth most common malignancy in men and the seventh most common malignancy in women, accounting for 5% and 4% of all new cancer cases, respectively. The average age at diagnosis is 57 years, and up to 75% of patients are younger than 70 years of age. Melanoma is notorious for affecting young and middle-aged people, unlike other solid tumors, mainly affecting older adults. It is commonly found in patients younger than 55 years, and it accounts for the third-highest number of lives lost across all cancers.

Fig: 1 Melanoma types

II. CAUSES

Melanoma happens when something changes healthy melanocytes into cancer cells. Melanocytes are skin cells that make pigment that gives skin its color. The pigment is called melanin.[1][2]

i. Melanoma starts when melanocytes develop changes in their DNA. A cell's DNA holds the instructions that tell a cell what to do. In healthy cells, DNA gives instructions to grow and multiply at a set rate. The instructions tell the cells to die at a set time. In cancer cells, the DNA changes give different instructions. The changes tell the cancer cells to make many more cells quickly. Cancer cells can keep living when healthy cells would die. This causes too many cells. It isn't clear what changes the DNA in skin cells and how it leads to melanoma. It's likely a combination of factors, including environmental and genetic factors. Still, healthcare professionals believe exposure to ultraviolet light is the leading cause of melanoma.[5]6]

The exact cause of all melanomas isn't clear. Most melanomas are caused by exposure to ultraviolet light. Ultraviolet light, also called UV light, comes from sunlight or tanning lamps and beds. Limiting exposure to UV light can help reduce the risk of melanoma.[7][8][9]

ii. The risk of melanoma seems to be increasing in people under 40, especially women. Knowing the symptoms of skin cancer can help ensure that cancerous changes are detected and treated before the cancer has spread. Melanoma can be treated successfully if it is found early.[15][16]

People may experience: Common symptoms: bigger mole diameter, darkening of the skin, mole colour changes, or skin mole with irregular border

III. SYMPTOMS

The first melanoma signs and symptoms often are:
A change in an existing mole. The development of a new pigmented or unusual-looking growth on the skin. Melanoma doesn't always begin as a mole. It also can happen on otherwise healthy skin. Melanomas symptoms can happen anywhere on the body.[11][13]

Melanomas most often develop in areas that have had exposure to the sun. This includes the arms, back, face and legs. Melanomas also can happen in areas that aren't as exposed to the sun. This includes the soles of the feet, palms of the hands and fingernail beds. Melanoma also can happen inside the body. These hidden melanomas are more common in people with brown or Black skins [15][16]

IV. RISK FACTORS

Factors that may increase the risk of melanoma include :

- A family history of melanoma
- A history of sunburns
- Explore to UV lights
- Having many mole or moles that aren't typical
- Living closer to equator or at higher elevation
- Skin that sunburns easily
- Weak immune system[16][17][18]

V. PREVENTION

You can reduce your risk of melanoma and other types of skin cancer if you:

1. Avoiding tanning lamps and beds
2. Avoid the sun during the middle of the day
3. Become familiar with your skin, so that you'll notice changes
4. Wear protective clothing
5. Wear sunscreen year – round[17][18][19]



Fig: Benign and Malignant tumors as seen in microscope

VI. DIAGNOSIS

Biopsy and pathological examination of a skin lesion; A skin exam checks for moles, birthmarks, or other pigmented areas that look abnormal in color, size, shape, or texture. During a biopsy, your doctor may remove all or part of the abnormal skin and a small amount of normal tissue around it. A pathologist looks at the tissue under a microscope to check for cancer cells.[19][20]

VII. TREATMENT

There are different types of treatment for patients with melanoma. The following types of treatment are used:

1. Surgery
2. Chemotherapy
3. Radiation therapy
4. Immunotherapy
5. Targeted therapy [3][4]

New types of treatment are being tested in clinical trials., Vaccine therapy

Treatment for melanoma may cause side effects. Patients may want to think about taking part in a clinical trial. Patients can enter clinical trials before, during, or after starting their cancer treatment. Follow-up tests may be needed.[3]

A. Surgery – Mohn's Surgery: surgical removal of skin cancer, one layer at a time, untill only healthy tissue is left.
B. Radiation therapy – treatment that uses X-rays and other high energy rays to kill abnormal cells.
C. Chemotherapy – unwanted reactions to drugs given for the purpose of killing cancer cells.
D. Immunotherapy – lower or changes normal immune response to treat the disease, especially cancer.
E. Other methods – it includes: skin grafting – surgically removing of skin from one part of the body and transplanting in to the other part. For example – to treat a serious burns or wounds.

wide local excision – surgical removal of a small areas of tissue, along with a margin of a normal tissue beyond the border of disease.[4][5][6]

VIII. APPROACHES

Malignant melanoma is the deadliest form of skin cancer, and has, among cancer types, one of the most rapidly increasing incidence rates in the world. Early diagnosis is crucial, since if detected early, its cure is simple. In this paper, we present an effective approach to melanoma identification from dermoscopic images of skin lesions based on ensemble classification. First, we perform automatic border detection to segment the lesion from the background skin. Based on the extracted border, we extract a series of colour, texture and shape features. The derived features are then employed in a pattern classification stage for which we employ a novel, dedicated ensemble learning approach to address the class imbalance in the training data and to yield improved classification performance. Our classifier committee trains individual classifiers on balanced subspaces, removes redundant predictors based on a diversity measure and combines the remaining classifiers using a neural network fuser. Experimental results on a large dataset of dermoscopic skin lesion images show our approach to work well, to provide both high sensitivity and specificity, and our presented classifier ensemble to lead to statistically better recognition performance compared to other dedicated classification algorithms.[4][5]

Since its inception in the mid-twentieth century, the field of artificial intelligence (AI) has undergone numerous transformations and retreats. Using large datasets, powerful computers, and modern computational methods, the subset of AI known as machine learning can identify complex patterns in real-world data, yielding observations, associations, and predictions that can match or exceed human capabilities. After decades of promise, the field stands poised to influence a broad range of human endeavors, from the most complex strategic games to autonomous vehicle navigation, financial engineering, and health care. Therefore, the purpose of this chapter is to provide an introduction to AI approaches and medical applications while elaborating on the role of AI in malignant melanoma detection and diagnosis from a healthcare provider and consumer perspective. It is critical that we continue to balance the opportunity and threat of AI in malignant melanoma, as this technology becomes more robust to maximize an effective implementation.[7][8]

Melanoma stem cells, also known as malignant melanoma-initiating cells, are identifiable through expression of specific biomarkers such as ABCB5 (ATP-binding cassette, sub-family B (MDR/TAP), member 5), NGFR (nerve growth factor receptor, CD271) and ALDH (aldehyde dehydrogenase), and drive melanoma initiation and progression based on prolonged self-renewal capacity, vasculogenic differentiation and immune evasion. As we will review here, specific roles of these aggressive subpopulations have been documented in tumorigenic.[7][8][9]

The incidence of cutaneous melanoma has risen at a rate significantly higher than that for other malignancies. This increase persists despite efforts to educate the public about the dangers of excess exposure to UV radiation from both the sun and tanning beds. Melanoma affects a relatively younger population and is notorious for its propensity to metastasize and for its poor response to current therapeutic regimens. These factors make prevention an integral component to the goal of decreasing melanoma-related mortality. Transformation of melanocytes into malignant melanoma involves the interplay between genetic factors, UV exposure, and the tumor microenvironment. The roles of UV radiation in the etiology of melanoma are mediated by both direct damage of DNA through formation of photoproducts and production of reactive oxygen species (ROS). Many of the promising antioxidant agents under development for the prevention of melanoma are derived from foodstuffs. B-Raf is a member of the Raf kinase family of serine/threonine-specific protein kinases that plays a role in regulating the MAP kinase/ERKs signaling pathway [15][16].

About 50 % of melanomas harbor activating BRAF mutations. BRAF mutations are found in 59 % of the melanomas arising in skin with intermittent sun exposure, such as trunk and arms, as compared with only 23 % of the acral melanomas, 11 % of mucosal melanomas, and 0 % of uveal melanomas. Two new agents, ipilimumab and vemurafenib, have been shown to improve outcome of advanced melanoma as presented at the plenary session of the 2011 annual meeting of the American Society of Clinical Oncology. Vemurafenib is the first personalized compound which demonstrated an improvement in progression-free survival (PFS) and overall survival (OS) in metastatic melanoma harboring the BRAFV600 mutation and represents the first drug of a class that exerts its anti-proliferative activity through inhibition of a highly specific molecular target. GSK2118436 (dabrafenib), the second BRAF inhibitor, in phase I and II trial obtained similar results to vemurafenib. A phase III trial is now ongoing. Taken together, the early clinical development of vemurafenib and dabrafenib clearly confirms that BRAF inhibitors can halt or reverse disease in patients with melanomas carrying this mutation, improving survival times compared with historically standard treatments (chemotherapy and interleukin-2). The clinical development of other new BRAF inhibitors such as RAF265 and LGX818 is now ongoing. Combination strategies of BRAF inhibitors with ipilimumab, an anti-CTLA-4 antibody, and/or MEK inhibitors or metformin are now under investigation in clinical trials.[18][19][20]



Table: Bibliometric Analysis





Fig: Stating the site of melanoma

CONCLUSION

It causes the vast majority of skin cancer deaths because other parts of the body. If melanoma is detected early and while it is still localized in the skin, most patients survive for at least five years. This study used bibliometric and Google Trends analyses to update the topics and to compare the differences and similarities of research interest and public interest in melanoma. Regarding research interest, the top 15 most frequently cited articles each year focused on immunotherapy (n=8), omics (n=5), and the microbiome (n=2). Regarding public interest, diseases associated with or manifestations of melanoma, treatment options, risk factors, diagnostic tools, and prognosis were of the greatest interest to the public. The results revealed the trends in research interest and public interest in melanoma, which may pave the way for further research.

REFERENCES

[1] Barker CA, Salama AK. New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma. J Natl Compr Canc Netw. 2018 May;16(5S):646-650. [PubMed]

[2] Reserva J, Janeczek M, Joyce C, Goslawski A, Hong H, Yuan FN, Balasubramanian N, Winterfield L, Swan J, Tung R. A Retrospective Analysis of Surveillance Adherence of Patients after Treatment of Primary Cutaneous Melanoma. J Clin Aesthet Dermatol. 2017 Dec;10(12):44-48. [PMC free article] [PubMed]

[3] Blakely AM, Commissions DS, Vezeridis MP, Miner TJ. Suboptimal Compliance With National Comprehensive Cancer Network Melanoma Guidelines: Who Is at Risk? Am J Clin Oncol. 2018 Aug;41(8):754-759. [PubMed]

[4] Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, DiMaio D, Fields RC, Fleming MD, Gastman B, Gonzalez R, Guild V, Johnson D, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A. NCCN Guidelines Insights: Melanoma, Version

3.2016. J Natl Compr Canc Netw. 2016 Aug;14(8):945-58. [PubMed]

[5] Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, DiMaio D, Ernstoff M, Fields RC, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A. Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Apr;14(4):450-73. [PubMed]

[6] Ferguson SD, Bindal S, Bassett RL, Haydu LE, McCutcheon IE, Heimberger AB, Li J, O'Brien BJ, Guha-Thakurta N, Tetzlaff MT, Tawbi H, Davies MA, Glitza IC. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neurooncol. 2019 May;142(3):499-509. [PubMed]

[7] Cho SI, Lee J, Jo G, Kim SW, Minn KW, Hong KY, Jo SJ, Cho KH, Kim BJ, Mun JH. Local recurrence and metastasis in patients with malignant melanomas after surgery: A single-center analysis of 202 patients in South Korea. PLoS One. 2019;14(3):e0213475. [PMC free article] [PubMed]

[8] Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T. Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma. Clin Exp Immunol. 2019 Jul;197(1):74-82. [PMC free article] [PubMed]

[9] Ott PA. Intralesional Cancer Immunotherapies. Hematol Oncol Clin North Am. 2019 Apr;33(2):249-260. [PubMed]

[10] Tarhini A, Atzinger C, Gupte-Singh K, Johnson C, Macahilig C, Rao S. Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA. J Comp Eff Res. 2019 May;8(7):461-473. [PubMed]

[11] Ghazawi FM, Darwich R, Le M, Rahme E, Zubarev A, Moreau L, Burnier JV, Sasseville D, Burnier MN, Litvinov IV. Uveal melanoma incidence trends in Canada: a national comprehensive population-based study. Br J Ophthalmol. 2019 Dec;103(12):1872-1876. [PubMed]

[12] Donley GM, Liu WT, Pfeiffer RM, McDonald EC, Peters KO, Tucker MA, Cahoon EK. Reproductive factors, exogenous hormone use and incidence of melanoma among women in the United States. Br J Cancer. 2019 Apr;120(7):754-760. [PMC free article] [PubMed]

[13] Hayek SA, Munoz A, Dove JT, Hunsinger M, Arora T, Wild J, Shabahang M, Blansfield J. Hospital-Based Study of Compliance with NCCN Guidelines and Predictive Factors of Sentinel Lymph Node Biopsy in the Setting of Thin Melanoma Using the National Cancer Database. Am Surg. 2018 May 01;84(5):672-679. [PubMed]

[14] Janz TA, Neskey DM, Nguyen SA, Lentsch EJ. Is imaging of the brain necessary at diagnosis for cutaneous head and neck melanomas? Am J Otolaryngol. 2018 Sep-Oct;39(5):631-635. [PubMed]

[15] Barker CA, Salama AK. New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma. J Natl Compr Canc Netw. 2018 May;16(5S):646-650. [PubMed]

[16] The fraction of cancer attributable to known risk factors in England, Wales, Scotland, Northern Ireland, and the UK overall in 2015

[17] KF Brown and others British Journal of Cancer, 2018. Volume 118, issue 8, pages 1130 to1141

[18] Ross and Wilson Anatomy and Physiology in Health and Illness (14th edition) A Waugh and A Grant Elsevier Ltd, 2023

[19] AJCC Cancer Staging Manual (8th edition) American Joint Committee on Cancer Springer, 2017

[20] Cancer: Principles and Practice of Oncology (12th edition) VT DeVita, TS Lawrence, SA Rosenberg Wolters Kluwer, 2022